TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05864560

Intervention type: DEVICE
Intervention: Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System
Description: Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).
Study: NCT05891509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Hematoma Evacuation
Description: Procedure of minimally invasive hematoma evacuation PLUS best medical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Therapy
Description: Best medical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Medical Therapy
Description: Best medical therapy
Study: NCT04698031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment
Description: After randomization, patients will receive clopidogrel 75 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Description: After randomization, patients will receive Aspirin 325 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
Study: NCT05876741

Intervention type: DIAGNOSTIC_TEST
Intervention: history taking , vital signs and labaratory investigations
Description: 1. Complete history taking:~   With stress on age, sex, epigastric pain, comorbidities (ischemic heart disease, diabetes, liver cirrhosis, renal failure, malignancy), syncope, disturbed conscious level, blood transfusion, drug history .~2. Clinical examination:~   Pulse, blood pressure, calculating the shock index, pallor, jaundice, cachexia, purpura, ecchymosis, conscious level, abdominal examination.~3. Laboratory investigations:~   * Complete blood count (CBC).~  * Creatinine and blood urea nitrogen (BUN).~  * liver function tests (serum bilirubin, serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), prothrombin concentration (PC), and international normalized ratio (INR)).~  * Serum electrolytes and arterial blood gases.~  * Fasting blood sugar.~4. Assessment of risk and predicting outcomes by:~   * Pre-endoscopic Rockall score (pRS).~  * Glasgow-Blatchford score (GBS).~  * AIMS65 score.~  * ABC score.~  * Horibe score.
Study: NCT05543525

Intervention type: OTHER
Intervention: Echocardiography
Description: Transthoracic echocardiography

Intervention type: OTHER
Intervention: Echocardiography
Description: Transthoracic echocardiography

Intervention type: OTHER
Intervention: Cardiopulmonary exercise testing
Description: Cardiopulmonary exercise testing

Intervention type: OTHER
Intervention: Cardiopulmonary exercise testing
Description: Cardiopulmonary exercise testing
Study: NCT06340828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washing Microbiota Transplantation
Description: Fecal samples from healthy adults were collected and underwent multiple centrifugations and filtrations to obtain a bacterial solution, which was then transplanted into the duodenum of patients via a nasogastric tube.
Study: NCT06073353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE-M
Description: THRIVE-M is a self-administered psychosocial mobile application for patients living with multiple myeloma that includes the following five modules:~1. Health module - teaching patients about physical symptoms and strategies to cope with physical symptoms~2. Relationships module - helping patients articulate different support needs and communication styles in navigating relationships~3. emotions module - helping patients identify connections between thoughts, feelings, and behaviors, as well as helpful states of mind and gratitude~4. Lifestyle module - helping patients practice skills for saving up energy and using self-care strategies~5. Reflection module - teaching patients to reflect on their lives, meaningful relationships, and sense of purpose.~Each module takes about 15-20 minutes to complete and participants will be instructed to complete all modules within an eight-week period.
Study: NCT06287528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 19-28z/IL-18 CAR T cells
Description: 19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 19-28z/IL-18 CAR T cells
Description: 19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 19-28z/IL-18 CAR T cells
Description: 19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL
Study: NCT04728061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gen1E-1124
Description: Intravenously-infused Gen1E-1124 in vehicle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gen1E-1124
Description: Intravenously-infused Gen1E-1124 in vehicle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenously-infused vehicle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenously-infused vehicle.
Study: NCT04832685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BrainSonix Pulsar 1002
Description: Device that delivers low intensity focused ultrasound

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BrainSonix Pulsar 1002
Description: Device that delivers low intensity focused ultrasound
Study: NCT05007977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 low dose
Description: Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 low dose
Description: Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 high dose
Description: Single SC injection of ZT-01 20 mg during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 high dose
Description: Single SC injection of ZT-01 20 mg during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 high dose
Description: Single SC injection of ZT-01 20 mg during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 high dose
Description: Single SC injection of ZT-01 20 mg during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 high dose
Description: Single SC injection of ZT-01 20 mg during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-01 high dose
Description: Single SC injection of ZT-01 20 mg during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single SC injection of placebo during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single SC injection of placebo during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single SC injection of placebo during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single SC injection of placebo during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single SC injection of placebo during hypoglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single SC injection of placebo during hypoglycemic clamp
Study: NCT05997667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rechargeable implantable deep brain stimulation system
Description: The DBS system will be implanted in subjects in both study arms. Subjects in experimental group will receive stimulation of DBS system within 1 month after surgery.

Intervention type: DEVICE
Group type: OTHER
Intervention: Rechargeable implantable deep brain stimulation system
Description: The DBS system will be implanted in subjects in both study arms. Subjects in control group will receive stimulation of DBS system at 3 months after surgery.
Study: NCT05595018

Intervention type: OTHER
Intervention: End user
Description: Participants will provide their opinions in two rounds to reach consensus

Intervention type: OTHER
Intervention: Demand side- management
Description: Participants will provide their opinions in two rounds to reach consensus

Intervention type: OTHER
Intervention: Supply side
Description: Participants will provide their opinions in two rounds to reach consensus

Intervention type: OTHER
Intervention: Funder
Description: Participants will provide their opinions in two rounds to reach consensus

Intervention type: OTHER
Intervention: Academia
Description: Participants will provide their opinions in two rounds to reach consensus
Study: NCT05849818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: full-immersive VRapeutic software gaming technology
Description: * Children of the study group will receive VR training sessions 3 times per week for 8 successive weeks.~* Viblio VRapeutic fully immersive game will be used.~* Manual instructions of the game will be followed and features of the game will be customized.~* The child instructed to put back a pile of books on the floor into their shelves.~* Level II of the game we will use audio visual distractors , repeated parrot sound and the child is required to order the books by colors~* Level III distracting tasks during book ordering~* The complexity of the game depend on task duration, number of books and the nature of distractors
Study: NCT05953948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intelligent Case Manage Platform (ICMP) and self-management program
Description: This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.
Study: NCT05938543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces an electrical current in neurons and allows for modulation of neural circuitry.~Other Name: iTBS
Study: NCT06221514

Intervention type: OTHER
Group type: OTHER
Intervention: Core Strengthening Programs
Description: The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions.

Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder Strengthening Programs
Description: The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions.
Study: NCT05255042

Intervention type: OTHER
Intervention: organ and tissue sample collection only
Description: Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology
Study: NCT05512702

Intervention type: DRUG
Intervention: Tissue Plasminogen Activator, Alteplase
Description: Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.

Intervention type: DRUG
Intervention: Low-molecular weight heparin
Description: Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
Study: NCT05759468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Product - MIB 626
Description: The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
Study: NCT06162091

Intervention type: OTHER
Intervention: Data collection
Description: The study will involve at the time of entry into the rehabilitation setting, the collection of data related to demographic and clinical variables assessing:~1. The Level of responsiveness (Coma Recovery Scale -revised (CRS-r);~2. Cognitive functioning (Levels of Cognitive Functioning, LCF);~3. disability (Disability Rating Scale, DRS);~4. level of care needed (Early Rehabilition Barthel Index, ERBI)~The Final outcome measure will be the Glasgow Outcome Scale- Extended (GOSE). It will also collect data on clinical variables and presence of medical devices (e.g. decompressive craniectomy, hydrocephalus, tracheostomy, respiration). For all evaluations, two monthly timepoints will be conducted for a total of 12 timepoints until discharge (0 -6 months). If the patient will be hospitalized for more than 6 months, the assessment will be done monthly up to 12 months.
Study: NCT05705752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: 12 sessions of balance training en 4 weeks, with a duration of 40-45 min each.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates training
Description: 12 sessions of Pilates training en 4 weeks, with a duration of 40-45 min each.
Study: NCT04845191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: hAd5-S-Fusion+N-ETSD is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen S fusion protein and N with an enhanced T-cell stimulation domain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAd5-S-Fusion+N-ETSD vaccine
Description: hAd5-S-Fusion+N-ETSD is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen S fusion protein and N with an enhanced T-cell stimulation domain.
Study: NCT06605196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resources and guided facilitation
Description: Participants in the intervention arm will participate in a planning period at the beginning of the intervention period to establish the goals for the partnership. The investigators will use the prioritized list of AHD partnership features developed in prior research to guide the initial planning period and then assist the partnership members to plan to implement the corresponding strategies focused on their areas of interest (e.g., developing collaborative projects, hiring faculty, staff, or students to conduct data analysis). The investigators will use telephone, email communication, and video conferencing to communicate with AHD partnerships, regularly assess progress towards goals, and adjust goals and strategies based on the progress. One additional in person visit to each AHD partnership in the intervention arm will be made in year 2 of implementation to review goals and progress and provide additional guidance and tailored support as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Existing resources
Description: Individuals will be referred to existing resources in the Learning Community.
Study: NCT06511297

Intervention type: DIAGNOSTIC_TEST
Intervention: comprehensive metabolic phenotyping
Description: The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Intervention type: DIAGNOSTIC_TEST
Intervention: comprehensive metabolic phenotyping
Description: The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Intervention type: DIAGNOSTIC_TEST
Intervention: comprehensive metabolic phenotyping
Description: The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Intervention type: DIAGNOSTIC_TEST
Intervention: comprehensive metabolic phenotyping
Description: The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Intervention type: DIAGNOSTIC_TEST
Intervention: comprehensive metabolic phenotyping
Description: The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
Study: NCT05731076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management support nutrition and exercise intervention
Description: Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
Study: NCT05278364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5007
Description: a RET selective Inhibitor
Study: NCT05863923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Messaging to Motivate Quitline use and Quitting among Persons Living With HIV (PLWH) in Vietnam (M2Q2-HIV)
Description: Participants in the intervention group will be exposed to the texting intervention through a series of culturally tailored assessments and motivational text messages from the text messaging system sent throughout the 6 months of duration of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: M2Q2-HIV Comparison
Description: Participants in the comparison group will be exposed to a brief set of five texts with facts about smoking risks and assessment messages that are not culturally tailored from the text messaging system.
Study: NCT04971473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhTSH
Description: Scanning was done 48 hours after the radioiodine administration. Each patient was scanned first following rhTSH and then scanned after thyroid hormone withdrawal.
Study: NCT05894421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2223 injection+ Penpulimab Injection
Description: TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
Study: NCT05107687

Intervention type: BEHAVIORAL
Intervention: Smoking cessation
Description: Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.~Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.~The subject selects their preferred intervention.

Intervention type: BEHAVIORAL
Intervention: Smoking cessation
Description: Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.~Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.~The subject selects their preferred intervention.
Study: NCT05871034

Intervention type: PROCEDURE
Group type: OTHER
Intervention: phacoemulsification
Description: cataract extraction

Intervention type: PROCEDURE
Group type: OTHER
Intervention: phacoemulsification
Description: cataract extraction
Study: NCT05445869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSomnus® EVO Sleep and Snore Device
Description: The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.
Study: NCT05119998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI325 + sintilimab
Description: IBI325 + sintilimab combination does-escalation Patients will receive IBI325 and sintilimab until progressive disease, intolerability, or other reasons leading to treatment discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI325
Description: IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation
Study: NCT05280223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyalase
Description: injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
Study: NCT06353620

Intervention type: DIAGNOSTIC_TEST
Intervention: High Density EEG recording
Description: Recording of resting state high density EEG (128 channels)

Intervention type: DIAGNOSTIC_TEST
Intervention: High Density EEG recording
Description: Recording of resting state high density EEG (128 channels)

Intervention type: DIAGNOSTIC_TEST
Intervention: Rey Complex Figure Test
Description: Memeory functioning evaluation

Intervention type: DIAGNOSTIC_TEST
Intervention: Rey Complex Figure Test
Description: Memeory functioning evaluation